Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

October 4, 2011 4 October, 2011

Sernova to Present at Biopartnering Europe Conference

Source: Sernova Corp.

LONDON, ONTARIO--(Marketwire -- October 4, 2011) - Sernova Corp. (TSX VENTURE:SVA) today announced that the Company will present to a select group of biotech industry investors and potential alliance partners at the BioPartnering Europe Conference, in London, England, at 2:30 p.m. at the QE II Conference Center on October 10th, 2011.

Sernova's President & Chief Executive Officer, Dr. Philip Toleikis, will provide an update on Sernova's recent advances including pre-clinical studies, contract manufacturing for clinical studies and progress towards advancement of the Company's Cell Pouch SystemTM into human clinical trials. Sernova Corp was sponsored for this conference in part by the Ontario Ministry of Economic Development and Trade and is part of the Ontario mission to BioPartnering Europe.

"With the consistent preclinical results demonstrating insulin independence using the Cell PouchTM in multiple preclinical models of diabetes and upcoming evaluation in diabetic patients, BioPartnering Europe provides an ideal venue to showcase Sernova's ground breaking technologies and conduct one on one meetings with potential corporate alliance partners and investors," said Dr. Philip Toleikis, President and CEO of Sernova Corp.

The Cell Pouch SystemTM is a proprietary medical device which may offer a significant improvement over the current practice of injecting therapeutic cells into blood vessels. Based on pre-clinical studies in four models, the Cell Pouch SystemTM becomes a vascularised organ-like endocrine structure when placed in the body under the skin, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in stringent small and large animal models of diabetes and has shown the device with insulin-producing islets controls blood glucose levels long-term, eliminating the need for daily insulin injections. This has now been demonstrated in isograft, autograft (self-tissue) and allograft (donor tissue) studies using substantially lower doses of islets than typically used for portal vein delivery, the current standard of care. Furthermore, Sernova believes the Cell Pouch SystemTM has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases and is currently seeking corporate partnerships as part of a strategy to demonstrate the broad utility of the Cell Pouch SystemTM.

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch SystemTM to provide a safe and efficacious environment for therapeutic cells and SertolinTM, a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.